PTC Inc

PTC Inc. unveils an AI engine to boost product lifecycle and quality‑management, while PTC Therapeutics gains Health Canada approval for Sephience™—a rare‑disease drug for PKU, signaling a dual‑front tech and pharma expansion.

PTC Inc. is trading near its 12‑month midpoint—stable but premium. Explore how its strong EBITDA, digital‑twin gaps, and AI opportunities weigh against regulatory risks and fierce competition.

PTC Inc. has announced a series of strategic milestones across various technology sectors, including security, CAD, warranty management, and defense, solidifying its position as a diversified and innovative global technology solutions provider.

PTC Inc. has experienced a 146% increase in market value over the last five years, driven by its robust position in the Product Lifecycle Management (PLM) ecosystem, which is forecasted to grow at a 7.4% compound annual growth rate from 2026 to 2032.

PTC Inc. is poised for continued growth, with its stock value more than doubling from its 52-week low and industry analysts predicting a significant increase in its stock value over the next three years.

PTC Inc.’s stock price surged significantly after securing a major contract worth over ₹100 crore from BrahMos Aerospace for the supply of titanium castings.

PTC Inc’s stock price has declined after the FDA rejected its oral drug for a rare genetic disorder, citing efficacy concerns.

PTC Inc continues to impress investors with its steady stock price growth and strong financial foundation, while its separate entity PTC Therapeutics also sees a boost in stock price target.

PTC Inc. has reported strong Q3 earnings, exceeding market expectations, and has raised its annual forecast, driven by robust demand for its design software products.

PTC Inc’s stock price and market valuation continue to rise, solidifying its position as a leader in the Product Lifecycle Management (PLM) market.